中国临床药理学杂志2018，Vol.34Issue(3)：224-227,4.DOI:10.13699/j.cnki.1001-6821.2018.03.010
瑞舒伐他汀钙片联合厄贝沙坦片治疗老年原发性高血压肾病的临床研究
Clinical trial of rosuvastatin calcium tablets combined with irbesartan tablets in the treatment of elderly primary hypertension nephropathy
摘要
Abstract
Objective To observe the clinical efficacy and safety of rosuvastatin calcium tablets combined with irbesartan tablets in the treatment of elderly primary hypertension nephropathy.Methods A total of 60 elderly patients with primary hypertension nephropathy were randomly divided into control group and treatment group with 30 cases per group.Control group was given irbesartan tablets 150 mg per time,qd,orally.Treatment group received rosuvastatin calcium tablets l0 mg per time,qd,orally,on the basis of control group.The clinical efficacy,liver function,renal function and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates in treatment and control groups were 93.33％ (28 cases/30 cases) and 90.00％ (27 cases/30 cases) without significant difference (P ＞0.05).After treatment,the main indexes in treatment and control groups were compared:the total cholesterol were (3.92 ± 0.67) and (5.54 ± 1.33)mmol · L-1,triglyceride were (1.61 ±0.45) and (2.16 ±0.84) mmol · L-1,low density lipoprotein cholesterol were (2.25 ± 0.62) and (2.76 ±0.84) mmol · L-1,serum creatinine were (75.70 ± 14.87) and (78.16 ± 18.84) μmol · L-1,blood urea nitrogen were (4.25 ± 0.99) and (5.03 ± 0.97) mmol · L-1,24 h urinary protein quantitation were (56.92±12.67) and (65.54 ± 16.33) μg · 24 h-1,β2-microspheres were (353.65 ± 27.43) and (389.16 ± 27.84) μg · L-1,serum cystatin C were (1.25 ± 0.32) and (1.61 ± 0.52) mg · L-1,high-sensitivity C-reactive protein were (15.45 ± 4.73) and (19.18 ± 5.63) mmol · L-1,the differences were significant (all P ＜ 0.05).The adverse drug reactions of two groups were based on nausea,vomiting and headache.The incidences of adverse drug reactions in treatment and control groups were 23.33％ and 20.00％ without significant difference (P ＞ 0.05).Conclusion Rosuvastatin calcium tablets combined with irbesartan tablets in the treatment of primary hypertension nephropathy in the elderly has the same clinical efficacy and safety as that of irbesartan tablet alone,but they can significantly improve the liver and kidney function of patients.关键词
瑞舒伐他汀钙片/厄贝沙坦片/老年/原发性高血压肾病/安全性Key words
rosuvastatin calcium tablet/irbesartan tablet/elderly/primary hypertension nephropathy/safety分类
医药卫生引用本文复制引用
徐新伟,赵军,尹芳,王佐良,王健英..瑞舒伐他汀钙片联合厄贝沙坦片治疗老年原发性高血压肾病的临床研究[J].中国临床药理学杂志,2018,34(3):224-227,4.基金项目
山东省潍坊市卫生局科研基金资助项目(2011-02012) （2011-02012）
